Latest market price
601.32
+5.19+0.87%
UTHRQT75United Therapeutics Corporation·NASDAQ
601.32+0.87%
Earnings
Up 0.9% — Reported earnings — EPS beat by 6%, revenue missed by 3%.
High confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E21.36EPS (ttm)27.91Insider Own0.90%Shs Outstand42.89MPerf Week1.71%
Market Cap25.57BForward P/E19.50EPS next Y30.57Insider Trans-80.46%Shs Float39.21MPerf Month12.10%
Enterprise Value22.91BPEG1.08EPS next Q6.01Short Float6.27%Perf Quarter15.86%
Income1.31BP/S8.10EPS this Y-2.98%Short Ratio3.50Perf Half Y5.09%
Sales3.15BP/B4.00EPS next Y14.67%ROA18.16%Short Interest2.46MPerf YTD23.41%
Book/sh149.22P/C9.60EPS next 5Y19.77%ROE20.18%52W High609.99 -1.42%Perf Year35.00%
Cash/sh62.06P/FCF23.37EPS past 3/5Y22.92% 19.28%ROIC17.69%52W Low430.02 39.84%Perf 3Y174.29%
Dividend Est.—EV/EBITDA13.66Sales past 3/5Y18.03% 16.50%Gross Margin86.14%Volatility1.77% 2.84%Perf 5Y215.74%
Dividend TTM—EV/Sales7.26EPS Y/Y TTM8.94%Oper. Margin44.49%ATR (14)16.20Perf 10Y437.85%
Dividend Ex-Date—Quick Ratio5.41Sales Y/Y TTM2.50%Profit Margin41.56%RSI (14)70.00Recom2.42
Dividend Gr. 3/5Y—Current Ratio5.73EPS Q/Q13.42%SMA206.16%Beta0.47Target Price673.67
Payout0.00%Debt/Eq0.00Sales Q/Q-2.00%SMA5013.34%Rel Volume0.83Prev Close596.13
Employees1,400LT Debt/Eq0.00EarningsNov 04SMA20012.85%Avg Volume716.91KPrice601.32
IPO DateJun 17, 1999Option/ShortYes / YesEPS/Sales Surpr.5.95% -2.65%Net Debt/EBITDA-1.59Volume592,555Change0.87%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-26-26ReiteratedCantor FitzgeraldOverweight$700 → $850
Oct-22-26ReiteratedRBC CapitalOutperform$708 → $697
Oct-20-26ReiteratedRaymond James$685 → $717
Oct-19-26ReiteratedUBSBuy$685 → $725
Oct-15-26ReiteratedGoldman SachsNeutral$321 → $368
Oct-14-26ReiteratedJefferiesBuy$575 → $728
Oct-08-26ReiteratedRBC CapitalOutperform$587 → $708
Oct-01-26UpgradeBTIGNeutral → Buy$728
Sep-24-26ReiteratedGoldman SachsNeutral$215 → $321
Aug-06-26ReiteratedMorgan StanleyEqual Weight$516 → $515
Latest News· Times ET
Oct-30-26
Oct-28-26
Oct-27-26
Oct-24-26
Oct-22-26
Oct-21-26
Oct-20-26
Oct-19-26
Oct-18-26
Oct-17-26
Oct-16-26
Oct-14-26
Company

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1553,1832,8772,328—————
Cost of Goods Sold Incl. D&A437384310258—————
Gross Profit2,7182,7982,5682,070—————
Selling, General and Administrative Excl. Other731731639477—————
Research and Development552550481408—————
Other Operating Expense300710—————
Operating Income1,4041,5171,3771,185—————
Interest Expense12204359—————
Unusual Expense
—————————
Non-Operating Income (Expense)183216205149—————
Net Income Before Taxes1,5731,7141,5391,274—————
Income Taxes262379344290—————
Consolidated Net Income1,3111,3351,195985—————
Net Income From Continuing Operations1,3111,3351,195985—————
Net Income1,3111,3351,195985—————
EPS (Recurring)30.2330.1326.4421.04—————
EPS (Basic, Before Extraordinaries)30.2330.1326.4421.04—————
EPS (Diluted)27.9127.8624.6419.81—————
EBITDA1,6771,8191,6541,387—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio21.5417.4914.3211.10—————
Price To Sales Ratio8.206.745.524.44—————
Gross Margin86.1587.9089.2688.92—————
Operating Margin44.5047.6647.8650.90—————
Net Margin41.5541.9441.5442.31—————
Shares Outstanding43444547—————
Market Capitalization25,85721,43915,87810,335—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$645.80$549.42$453.04$356.66$260.28● Close Price0.00M27.89M55.79M83.68M111.58MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ROTHBLATT MARTINE AChairperson & CEONov 02 '26Option Exercise117.769,5001,118,720333,943Nov 03
ROTHBLATT MARTINE AChairperson & CEONov 02 '26Sale596.229,5005,664,136324,443Nov 03
ROTHBLATT MARTINE AChairperson & CEOOct 30 '26Option Exercise117.769,5001,118,720333,943Nov 02
ROTHBLATT MARTINE AChairperson & CEOOct 30 '26Sale600.099,5005,700,856324,443Nov 02
ROTHBLATT MARTINE AChairperson & CEOOct 29 '26Option Exercise117.769,5001,118,720333,943Oct 30
ROTHBLATT MARTINE AChairperson & CEOOct 29 '26Sale594.789,5005,650,415324,443Oct 30
ROTHBLATT MARTINE AChairperson & CEOOct 28 '26Option Exercise117.769,5001,118,720333,943Oct 29
ROTHBLATT MARTINE AChairperson & CEOOct 28 '26Sale585.499,5005,562,190324,443Oct 29
ROTHBLATT MARTINE AChairperson & CEOOct 27 '26Option Exercise117.769,5001,118,720333,943Oct 28
ROTHBLATT MARTINE AChairperson & CEOOct 27 '26Sale587.739,5005,583,417324,443Oct 28
ROTHBLATT MARTINE AChairperson & CEOOct 26 '26Option Exercise117.769,5001,118,720333,943Oct 27
ROTHBLATT MARTINE AChairperson & CEOOct 26 '26Sale588.649,5005,592,092324,443Oct 27
ROTHBLATT MARTINE AChairperson & CEOOct 23 '26Option Exercise117.769,5001,118,720333,943Oct 26
ROTHBLATT MARTINE AChairperson & CEOOct 23 '26Sale582.769,5005,536,233324,443Oct 26
ROTHBLATT MARTINE AChairperson & CEOOct 22 '26Option Exercise117.769,5001,118,720333,943Oct 23
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.